🔗 Share this article WHO Raises Alert Over Critical Lack of Obesity Jabs Fewer than a tenth of people who could benefit from obesity jabs including Wegovy are able to get them, warns the global health agency as it issues its inaugural advice on the medications. Given over a billion people worldwide now living with obesity, it is calling for broader and more equitable access to this class of drugs. Per forecasts, more than two billion will be living with obesity by 2030 without intervention. "Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are significant obstacles to universal access to the jabs that can help people shift significant body mass, says the body. Weight-Loss Drug Scarcity Despite the present most optimistic scenario, the supply of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, according to the WHO. The advice calls on countries and companies to increase availability, via approaches such as patent sharing. The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is due to expire in a number of nations in 2026. How Weight-Loss Injections Work The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so people consume fewer calories. People commonly see weight reduction in the initial weeks of starting on the once-weekly jabs. Evidence indicates people may put most of the weight back on after a year of discontinuing the treatment, when their usual hunger resume. Being overweight or obese elevates your likelihood for experiencing diseases, like diabetes, heart disease, stroke, and specific cancers. Excess weight concerns people in every country and was associated with over three and a half million deaths worldwide in 2024, per the WHO.
Fewer than a tenth of people who could benefit from obesity jabs including Wegovy are able to get them, warns the global health agency as it issues its inaugural advice on the medications. Given over a billion people worldwide now living with obesity, it is calling for broader and more equitable access to this class of drugs. Per forecasts, more than two billion will be living with obesity by 2030 without intervention. "Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are significant obstacles to universal access to the jabs that can help people shift significant body mass, says the body. Weight-Loss Drug Scarcity Despite the present most optimistic scenario, the supply of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, according to the WHO. The advice calls on countries and companies to increase availability, via approaches such as patent sharing. The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is due to expire in a number of nations in 2026. How Weight-Loss Injections Work The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so people consume fewer calories. People commonly see weight reduction in the initial weeks of starting on the once-weekly jabs. Evidence indicates people may put most of the weight back on after a year of discontinuing the treatment, when their usual hunger resume. Being overweight or obese elevates your likelihood for experiencing diseases, like diabetes, heart disease, stroke, and specific cancers. Excess weight concerns people in every country and was associated with over three and a half million deaths worldwide in 2024, per the WHO.